Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.

ABSTRACT:

Objective

To perform an expedited assessment of cancer risk associated with exposure to N-nitrosodimethylamine (NDMA) through contaminated valsartan products.

Design

Nationwide cohort study.

Setting

Danish health registries on individual level prescription drug use, cancer occurrence, and hospital diagnoses.

Participants

5150 Danish patients with no history of cancer, aged 40 years or older, and using valsartan at 1 January 2012 or initiating use between 1 January 2012 and 30 June 2017. Participants were followed from one year after cohort entry (lag time period) until experiencing a cancer outcome, death, migration, or end of study period (30 June 2018). Each participant's exposure to NDMA (ever exposure and predefined categories of cumulative valsartan exposu

SUBMITTER: Pottegard A 

PROVIDER: S-EPMC6134800 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature